Proactive Investors - Run By Investors For Investors

Imugene reveals new data on cancer vaccine programs

Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone.
lecture theatre
KEY-Vaxx is a cancer vaccine designed to treat tumors such as lung cancer

Imugene Ltd (ASX:IMU) has welcomed new data being presented on its KEY-Vaxx and B-Vaxx cancer vaccine programs.

The data was presented by Dr Tanios Bekaii-Saabfrom the Mayo Clinic at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The highlight and key finding of the KEY-Vaxx presentation demonstrated that KEY-Vaxx, when combined with B-Vaxx, is more effective in reducing tumor growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone.

The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity.

Imugene is working to evaluate KEY-Vaxx and its potential efficacy in a range of cancers.

New data from phase Ib study of HER-Vaxx

New data was also presented at the same event related to the phase Ib study of the HER-Vaxx cancer vaccine, in which 11 out of 14 evaluable patients showed clinically meaningful responses.

The phase 1b HER-Vaxx study reported no safety or toxicity issues and all evaluable patients showed increased antibody responses.

One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.

Due to the success of the phase Ib trial, Imugene dosed its first patient in its phase II study in mid-March 2019.

Imugene’s managing director and CEO Leslie Chong said: “We are encouraged by the overall positive data from the phase Ib trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”

READ: Imugene gets development roadmap for cancer vaccine from FDA meeting

Recently, Imugene received minutes of its meeting with the (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

The meeting was aimed at seeking guidance on the studies required for phase I clinical development of KEY-Vaxx.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Long-term fundamentals remain firmly in the seafood specialist's favour
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use